Global Perspectives on Use of Osimertinib in EGFR+ NSCLC
Expert panelists Benjamin P. Levy, MD; Solange Peters, MD, PhD; Sanjay Popat, PhD, FRCP; David Planchard, MD, PhD; and Suresh S. Ramalingam, MD, provide personal perspectives on the sequencing of osimertinib for patients with EGFR-positive non–small cell lung cancer (NSCLC) given what is known about resistance mechanisms.
